Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®
August 03, 2021 at 01:30 pm IST
Share
Yuyu Pharma and Novartis Korea announced that the companies have entered into an agreement in which Yuyu will have exclusive distribution rights for the following prescription medicines in Korea: Lamisil® for the treatment of athlete's foot; Lescol® XL for the treatment of dyslipidemia; and the Tegretol® for the treatment of epilepsy. This agreement will be in effect beginning August 1st, 2021.
Yuyu Pharma, Inc. is a Korea-based company engaged in the provision of pharmaceutical products. The Company produces prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, anti-diabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, topical corticosteroids and others, as well as non-prescription drugs such as vitamins and digestive agents. It also provides healthcare supplements and quasi drugs. In addition, the Company is involved in the provision of medicines for geriatric diseases such as osteoporosis, dementia, stroke and others.
Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®